ALFA FinderNSE filing, NSE: LENSKART. Summary written from the filing by ALFA Finder's alert engine.
Lenskart Solutions Ltd: key numbers
- Share price
- ₹721.00
- Market cap
- ₹1,25,437 Cr
- Revenue (annual)
- ₹8,814 Cr
- Net profit (annual)
- ₹493.6 Cr
- P/E (TTM)
- 160.8×Sector 48.4×
- Promoter holding
- 17.52%-0.01% QoQ
- FII holding
- 18.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lenskart Solutions Ltd
All →Lenskart Solutions Employee Stock Options
Lenskart Solutions Limited has allotted 460,934 equity shares following an ESOP/ESPS exercise. The company's paid-up share capital increased from Rs. 347.86 Crore to Rs. 347.95 Crore.
Lenskart Solutions Earnings Call Transcript: Key Takeaways
Revenue rose 32.5% to ₹2,845 Cr and PAT more than doubled to ₹232 Cr. Management is confident on growth but hedges on the 25% long-term margin, which has no timeframe. Rupee weakness is the main product-margin headwind, and management says it is solved structurally over time.
Lenskart Solutions Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹2,845 Cr (+32.5%), EBITDA ₹624 Cr (21.9% margin), PAT ₹232 Cr (+106.1%). Store expansion and brand-portfolio launches drive growth.
Lenskart Solutions Results Update
Lenskart Solutions Limited reported Q2 FY27 revenue growth of 32.5% to ₹2,845 Crore. Net profit surged 2.1x to ₹232 Crore, supported by strong India SSSG.
- total active stores
- 3624.0 stores
Lenskart Solutions Q2 FY27 Results: Net Profit ₹232.4 Cr, Up 124.5% YoY
Lenskart Solutions Ltd reported revenue from operations of ₹2,845 Cr (+35.7% YoY) and net profit of ₹232.4 Cr (+124.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹232.4 Cr · +124.5% YoY
Lenskart Solutions Board Meeting Date
Lenskart Solutions Limited scheduled a board meeting for November 4, 2026, to consider and approve its unaudited standalone and consolidated financial results for the September 2026 quarter.
Other other announcement announcements
All →Bal Pharma Other Announcement
Bal Pharma filed a Reg 32 statement confirming no deviation in its ₹2.10 Cr preferential warrant proceeds, with nothing utilised by September 30, 2026. The amount remains fully unutilised.
- Value
- ₹2.10 Cr
Glottis Other Announcement
Glottis Limited filed its Reg 32 statement confirming no deviation in IPO fund utilisation for the quarter ended September 30, 2026. Gross proceeds of ₹15,999.87 Lakhs were raised, with ₹9,009.54 Lakhs utilised so far.
TGV SRAAC Other Announcement
TGV Sraac's board noted a CIN change, registered by MCA on 27 October 2026. It followed an objects clause alteration approved at the September 2026 AGM.
Manaksia Coated Metals & Industries Other Announcement
Manaksia Coated Metals filed its quarterly shareholding pattern, with promoters holding 51.93%. The filing is routine regulatory disclosure with no transaction or corporate event.
Network People Services Technologies Other Announcement
Network People Services Technologies reported a Reg 32 statement confirming no deviation in use of its Rs 300 Crore preferential allotment proceeds. Rs 56.52 Crore utilised by September 30, 2026, with the Audit Committee reviewing it.
Tata Power Company Other Announcement
Tata Power's auditor SRBC & Co issued a limited-assurance report confirming compliance with debenture trust deed covenants as at September 30, 2026. It is a routine Reg 56(1)(d) compliance certificate with no new money or business event.